NEW YORK (GenomeWeb) – CFD Research Corporation (CFDRC) has acquired the microbiome-based drug discovery division of iXpressGenes (iXG) for an undisclosed amount.

CFDRC and iXpressGenes are both associate companies of the HudsonAlpha Institute for Biotechnology in Huntsville, Alabama.

As part of the acquisition, CFDRC obtained iXG's high-throughput antimicrobial discovery platform, EMAD (extremophilic microbiome antimicrobial discovery), and all key personnel associated with the division, the companies said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.